Treatment of Paget's Disease - Taming the wild osteoclast

New England Journal of Medicine

Volumn 353, Issue 9, 2005, Pages 872-875

  Deftos, L J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA WESTERN SCHOOL OF LAW   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOTROPIN; ETIDRONIC ACID; GLUCOCORTICOID; INDOMETACIN; MITHRAMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPROTEGERIN; SALICYLIC ACID DERIVATIVE; ZOLEDRONIC ACID; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CELL RECEPTOR; GLYCOPROTEIN; IMIDAZOLE DERIVATIVE; TNFRSF11B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

BONE DISEASE; BONE METABOLISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; HOMEOSTASIS; HUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; BLOOD; BONE; METABOLISM; NOTE;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE RESORPTION; DIPHOSPHONATES; GLYCOPROTEINS; HUMANS; IMIDAZOLES; OSTEITIS DEFORMANS; OSTEOCLASTS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 24044444602     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp058184     Document Type: Short Survey

References (5)

1. Vaananen K. Mechanisms of osteoclast mediated bone resorption - rationale for the design of new therapeutics. Adv Drug Deliv Rev 2005;57:959-71.
2. Potts JT Jr, Deftos LJ. Parathyroid hormone, calcitonin, vitamin D, bone and bone mineral metabolism. In: Bondy PK, Rosenberg LE, eds. Duncan's diseases of metabolism. 7th ed. Philadelphia: W.B. Saunders, 1974:904-1082.
3. Fleisch H, Reszka A, Rodan G, Rogers M. Bisphosphonates: mechanisms of action. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. 2nd ed. Vol. 2. San Diego, Calif.: Academic Press, 2002:1361-86.
4. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
5. Odvina CV, Zerwekh JE, Rao DS, Maaloof N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.